Bayer wins FDA ok for hemophilia drug

Aug. 30, 2018

Bayer AG has received U.S. FDA approval for a Factor VIII hemophilia drug, called Jivi.

Jivi is used in preventative treatment of hemophilia A and is also approved for on-demand treatment. It is the third FDA-approved hemophilia A treatment in Bayer’s hemophilia portfolio.

Bayer has also submitted marketing authorization applications for Jivi in the European Union and Japan.

Read the press release